AZN241206C88000
- 0.00
- 0.000.00%
AstraZeneca Newsroom
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
Novo Nordisk and AstraZeneca Top of the 2025 Drug Picks for US Investment Bank - Read Why | NYSE:NVO
J.P. Morgan Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca Hits 4-week High
Sanofi will invest approximately 1 billion euros to build a new insulin production base in peking.
Sanofi will invest approximately 1 billion euros (about 1.1 billion US dollars) to build a new insulin production facility in Peking, marking its largest single investment in china to date and part of its broader global strategy to expand production capacity in asia. The French pharmaceutical company stated on WeChat that this will be Sanofi's fourth production facility in china and its second in Peking, focusing on meeting the medication needs of local diabetes patients. Sanofi is one of the largest insulin producers globally, and the potential in the diabetes treatment market in china is immense. Sanofi noted that as of 2021, around 0.14 billion adults in mainland china suffer from diabetes.
Sanofi Unveils $1 Billion China Investment to Boost Production
AstraZeneca PLC ADR Falls Monday, Underperforms Market
AstraZeneca Announces Share Capital and Voting Rights
Why AstraZeneca PLC (AZN) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
USA Stock Market Outlook | Three major equity index futures rise together, US retailers prepare for Black Friday, the market will close 3 hours early on Friday.
On November 29 (Friday) during pre-market trading, all three major equity index futures in the U.S. rose.
Astrazeneca (AZN.US) Class 1 new drug approved for clinical trials in China for the first time, aiming to develop treatment for heart failure.
Astrazeneca (AZN.US) has received an implied license for clinical trials of its Class 1 new drug AZD5462 in china, which is intended for the treatment of heart failure.
AstraZeneca Partner's Orpathys Secures Renewal on China's Drug Reimbursement List
AstraZeneca's Breast Cancer Drug Wins State Insurance Coverage in China
AstraZeneca's Strategic Focus and Clinical Trial Success Bolster Buy Rating
Failure of AstraZeneca's AZD4041 a Blow for Non-opioid OUD Treatments
Amgen (AMGN.US) released mid-term data on the weight loss therapy MariTide, showing weight loss effects comparable to Novo Nordisk.
Amgen announced on Tuesday that its experimental weight loss therapy MariTide achieved significant results in Phase 2 trials.
Astrazeneca (AZN.US) combination therapy Truqap phase 3 trial results are positive.
Astrazeneca (AZN.US) announced today the positive results of the CAPItello-281 Phase 3 clinical trial.
Astrazeneca's Capivasertib for prostate cancer has successfully completed Phase III trials, and the outlook for Kairui Pharmaceutical-B (2105.HK) AKT inhibitors is bullish.
On November 25th, AstraZeneca announced the success of its AKT inhibitor Capivasertib in the phase III CAPItello-281 study for the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Following the approval and launch of Capivasertib for breast cancer indications, this study further confirmed the clinical value of AKT inhibitors. AKT inhibitors, as drugs that have shown potential in multiple cancers such as breast cancer, prostate cancer, and ovarian cancer, have a very broad market outlook. In recent years, an increasing number of pharmaceutical companies have begun to pay attention to AKT inhibitors.
AstraZeneca Reports Positive Phase 3 Results for Truqap in Prostate Cancer